Get the Stockscreener App
11.60
1.45%
0.115
Oric Pharmaceuticals Inc stock is traded at $11.60, with a volume of 506.90K.
It is up +1.45% in the last 24 hours and down -7.57% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$11.48
Open:
$11.57
24h Volume:
506.90K
Relative Volume:
0.40
Market Cap:
$1.13B
Revenue:
-
Net Income/Loss:
$-137.25M
P/E Ratio:
-6.1349
EPS:
-1.89
Net Cash Flow:
$-121.97M
1W Performance:
-4.93%
1M Performance:
-7.57%
6M Performance:
+98.40%
1Y Performance:
+27.70%
1-Day Range:
$11.02
$11.70
1-Week Range:
$11.02
$12.71
52-Week Range:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
11.63 | 1.12B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.75 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.15 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
437.97 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.14 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.25 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Evercore ISI | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at Evercore ISI - MarketBeat
Evercore ISI Group Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Outperform Recommendation - MSN
Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know - MSN
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
ORIC Pharmaceuticals (ORIC) Initiates Coverage with Outperform Rating | ORIC Stock News - GuruFocus
Is ORIC Pharmaceuticals Inc. (4TZ) stock positioned for secular growthChart Signals & High Win Rate Trade Tips - newser.com
Why ORIC Pharmaceuticals Inc. (4TZ) stock attracts HNW investorsEarnings Risk Summary & Long-Term Safe Return Strategies - newser.com
Is ORIC Pharmaceuticals Inc. (4TZ) stock attractive for growth funds2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Can ORIC Pharmaceuticals Inc. stock resist sector downturnsJuly 2025 Drop Watch & Reliable Price Breakout Alerts - newser.com
Is ORIC Pharmaceuticals Inc. stock undervalued vs historical averagesEarnings Miss & Consistent Growth Stock Picks - newser.com
Why ORIC Pharmaceuticals Inc. (4TZ) stock benefits from AI revolutionQuarterly Market Summary & Risk Managed Investment Strategies - newser.com
Will ORIC Pharmaceuticals Inc. stock maintain momentum in 2025July 2025 Trends & Stepwise Trade Signal Guides - newser.com
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
ORIC: ORIC-944 demonstrates high ctDNA clearance and safety, supporting pivotal trials and market expansion - TradingView
Wolfe Research Initiates Coverage on Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Why institutional investors increase stakes in ORIC Pharmaceuticals Inc. (4TZ) stock2025 Risk Factors & Daily Profit Maximizing Tips - newser.com
The Technical Signals Behind (ORIC) That Institutions Follow - news.stocktradersdaily.com
Why ORIC Pharmaceuticals Inc. stock could see breakout soon2025 Technical Overview & Stock Portfolio Risk Management - newser.com
Is this a good reentry point in ORIC Pharmaceuticals Inc.2025 Historical Comparison & Stock Market Timing Techniques - newser.com
Analyst Initiation: Wolfe Research Rates ORIC Pharmaceuticals as 'Peer Perform' | ORIC Stock News - GuruFocus
JP Morgan Raises ORIC Pharmaceuticals (ORIC) Price Target to $20 - GuruFocus
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Can you recover from losses in ORIC Pharmaceuticals Inc.Weekly Volume Report & Entry and Exit Point Strategies - newser.com
Wolfe Research initiates coverage on ORIC Pharmaceuticals stock with Peerperform rating - Investing.com Canada
Citigroup Raises ORIC Pharmaceuticals Price Target to $16 | ORIC Stock News - GuruFocus
Relative strength of ORIC Pharmaceuticals Inc. in sector analysisJuly 2025 Market Mood & Target Return Focused Picks - newser.com
ORIC Pharma Surges Ahead With ORIC-944 And Enozertinib Data Momentum - RTTNews
Oric Pharmaceuticals' (ORIC) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Why analysts recommend ORIC Pharmaceuticals Inc. (4TZ) stockWeekly Investment Recap & Free Growth Oriented Trading Recommendations - newser.com
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - TipRanks
Wells Fargo & Company Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $19.00 - MarketBeat
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oric Pharmaceuticals Inc Stock (ORIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Oct 06 '25 |
Sale |
14.52 |
11,000 |
159,719 |
48,317 |
| Chacko Jacob | PRESIDENT AND CEO |
Oct 06 '25 |
Sale |
12.32 |
37,461 |
461,520 |
531,419 |
1.75%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):